Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F] fallypride positron emission tomography

International Journal of Geriatric Psychiatry

Volumn 29, Issue 10, 2014, Pages 1001-1009

  Clark Papasavas, Chloe ^a   Dunn, Joel T ^a   Greaves, Suki ^b   Mogg, Andrew ^b   Gomes, Rosemary ^a   Brownings, Stuart ^a   Liu, Kathy ^a   Nwosu, Bonnita ^a   Marsden, Paul ^a   Joemon, John ^a   Cleij, Marcel ^a   Kessler, Robert ^c   Howard, Robert ^a   Reeves, Suzanne ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Amisulpride; Antipsychotic; D2 3 occupancy; Psychosis; 18F fallypride

Indexed keywords

AMISULPRIDE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FALLYPRIDE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; FALLYPRIDE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG TOLERABILITY; FEMALE; HEAD MOVEMENT; HUMAN; IMAGE ANALYSIS; INFERIOR TEMPORAL GYRUS; MALE; MINI MENTAL STATE EXAMINATION; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; PUTAMEN; RECEPTOR OCCUPANCY; SAMPLING; THALAMUS; VERY ELDERLY; ANALOGS AND DERIVATIVES; BRAIN MAPPING; COMPLICATION; METABOLISM; PROCEDURES; PSYCHOTIC DISORDERS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BRAIN MAPPING; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; SULPIRIDE;

EID: 84908674641     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4090     Document Type: Article

References (42)

1. Ballard C, Howard R. 2006. Neuroleptic drugs in dementia: Benefits and harm. Nature Rev 7: 492-500.
2. 18F]fallypride binding in healthy humans. Synapse 62: 399-408.
3. Cummings JL, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
4. Dunn JT, Clark-Papasavas C, Marsden P, et al. 2013. Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people. J Cereb Blood Flow Metab 33: 1098-1103.
5. Farde L, Nordstrom AL, Wiesel FA, et al. 1992. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of general psychiatry, 49: 538-544.
6. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state". A practicalmethod for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
7. la Fougere C, Meisenzahl E, Schmitt G, et al. 2005. D2 receptor occupancy during high-And low-dose therapy with the atypical antipsychotic amisulpride: A 123I-iodobenzamide SPECT study. J Nucl Med 46: 1028-1033.
8. Howard R, Rabins PV, Seeman MV, et al. 2000. Late-onset schizophrenia and verylate-onset schizophrenia-like psychosis: An international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry 157: 172-178.
9. Innis RB, Cunningham VJ, Delforge J, et al. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
10. Jeste DV, Blazer D, Casey D, et al. 2008. ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33: 957-970.
11. Joyce JN, Murray AM, Hurtig HI, et al. 1998. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Neuropsychopharmacology 19: 472-480.
12. Kapur S, Remington G, Zipursky RB, et al. 1995. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci 57: PL103-PL107.
13. 18F]fallypride. Neuropsychopharmacology 33: 3111-3125.
14. Kessler RM, Ansari MS, Riccardi P, et al. 2005. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30: 2283-2289.
15. Kessler RM, Ansari MS, Riccardi P, et al. 2006. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31: 1991-2001.
16. Lammertsma AA, Bench CJ, Hume SP, et al. 1996. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16: 42-52.
17. Lim HK, Pae CU, Lee C, et al. 2006. Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: A randomized, open, prospective study. Neuropsychobiology 54: 247-251.
18. Martinez D, Slifstein M, Broft A, et al. 2003. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285-300.
19. Martinot JL, Paillere-Martinot ML, Poirier MF, et al. 1996. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl) (Berl) 124: 154-158.
20. Mauri M, Mancioli A, Rebecchi V, et al. 2006. Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease. Acta Neurol Scand 114: 97-101.
21. McKhann G, Drachman D, Folstein M, et al. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
22. Meisenzahl EM, Schmitt G, Grunder G, et al. 2008. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: An iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 41: 169-175.
23. Morris ED, Chefer SI, Lane MA, et al. 1999. Loss of D2 receptor binding with age in rhesus monkeys: Importance of correction for differences in striatal size. J Cereb Blood Flow Metab 19: 218-229.
24. 18F-fallypride in normal volunteers: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 46: 170-188.
25. Olsson H, Farde L. 2001. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy-A simulation study based on experimental data. Neuroimage 14: 936-945.
26. Reeves S, Stewart R, Howard, R. 2002. Service contact and psychopathology in verylate-onset schizophrenia-like psychosis: The effects of gender and ethnicity. Int J Geriatr Psychiatry 17: 473-479.
27. Reeves S, Brown R, Howard R, et al. 2009. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology 72: 528-534.
28. Reeves S, Brown R, Matthews D, et al. 2010. No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer's disease. J Neurol Neurosurg Psychiatry, 81: 119-121.
29. Reeves SJ, Gould RL, Powell JF, et al. 2012. Origins of delusions in Alzheimer's disease. Neurosci Biobehav Rev 36: 2274-2287.
30. Simpson GM, Angus JWS. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212(suppl): 11-19.
31. Sparshatt A, Taylor D, Patel MX, et al. 2009. Amisulpride -dose, plasma concentration, occupancy and response: Implications for therapeutic drug monitoring. Acta Psychiatr Scand 120: 416-428.
32. Stone, JM, Bressan, RA, Erlandsson, K, Ell, PJ, Pilowsky, LS (2005) Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. Psychopharmacology (Berl) (Berl), 180: 664-669.
33. Stone JM, Davis JM, Leucht S, et al. 2009. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs-An original patient data metaanalysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 35: 789-797.
34. Tziortzi AC, Searle GE, Tzimopoulou S, et al. 2011. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy. Neuroimage 54: 264-277.
35. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. 2002. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15: 273-289.
36. Uchida H, Kapur S, Mulsant BH, et al. 2009a. Sensitivity of older patients to antipsychotic motor side effects: A PET study examining potential mechanisms. Am J Geriatr Psychiatry 17: 255-263.
37. Uchida H, Mamo DC, Mulsant BH, et al. 2009b. Increased antipsychotic sensitivity in elderly patients: Evidence and mechanisms. J Clin Psychiatry 70: 397-405.
38. Uchida H, Suzuki T, Graff-Guerrero A, et al. 2012. Therapeutic window for striatal dopamine D2/3 receptor occupancy in older patients with schizophrenia: A pilot PET study. Am J Geriatr Psychiatry epub Nov 2012
39. Vernaleken I, Siessmeier T, Buchholz HG, et al. 2004. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 7: 421-430.
40. 18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J Clin Psychopharmacol 28: 608-617.
41. Vernaleken I, Peters L, Raptis M, et al. 2011. The applicability of SRTM in [(18)F] fallypride PET investigations: Impact of scan durations. J Cereb Blood Flow Metab 31: 1958-1966.
42. Xiberas X, Martinot JL, Mallet L, et al. 2001. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 21: 207-214.